@prefix dct: <http://purl.org/dc/terms/> .
@prefix this: <http://www.tkuhn.ch/bel2nanopub/RAnzijPY55802WFhmeUTANFkh5TgcPck9Sbq2-O8089QI> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RAnzijPY55802WFhmeUTANFkh5TgcPck9Sbq2-O8089QI#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix chebi: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=> .
@prefix sdis: <http://resource.belframework.org/belframework/1.0/namespace/selventa-legacy-diseases/> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix mesh: <http://purl.bioontology.org/ontology/MSH/> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .
sub:Head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}
sub:assertion {
   sub:_1 occursIn: mesh:D010053 , species:9606 ;
    rdf:object sdis:tumor%20growth ;
    rdf:predicate belv:decreases ;
    rdf:subject chebi:3722 ;
    a rdf:Statement .
  sub:assertion rdfs:label "a(CHEBI:cisplatin) -| path(SDIS:\"tumor growth\")" .
}
sub:provenance {
   beldoc: dce:description "Approximately 61,000 statements." ;
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved." ;
    dce:title "BEL Framework Large Corpus Document" ;
    pav:authoredBy sub:_3 ;
    pav:version "1.4" .
  sub:_2 prov:value "Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. MCJ expression was associated with enhanced sensitivity to paclitaxel, topotecan, and cisplatin, suggesting that MCJ loss may play a role in de novo chemoresistance in ovarian carcinoma." ;
    prov:wasQuotedFrom pubmed:11358853 .
  sub:_3 rdfs:label "Selventa" .
  sub:assertion prov:hadPrimarySource pubmed:11358853 ;
    prov:wasDerivedFrom beldoc: , sub:_2 .
}
sub:pubinfo {
   this: dct:created "2014-07-03T14:29:56.233+02:00"^^xsd:dateTime ;
    pav:createdBy orcid:0000-0001-6818-334X , orcid:0000-0002-1267-0234 .
}